MX9304925A - Composiciones terapeuticas contra el cancer para profilaxis o para el tratamiento de cancer. - Google Patents

Composiciones terapeuticas contra el cancer para profilaxis o para el tratamiento de cancer.

Info

Publication number
MX9304925A
MX9304925A MX9304925A MX9304925A MX9304925A MX 9304925 A MX9304925 A MX 9304925A MX 9304925 A MX9304925 A MX 9304925A MX 9304925 A MX9304925 A MX 9304925A MX 9304925 A MX9304925 A MX 9304925A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
prophylaxis
therapeutic compositions
compositions against
Prior art date
Application number
MX9304925A
Other languages
English (en)
Inventor
Phil Gold
Gustavo Bounous
Original Assignee
Immunotec Res Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotec Res Corp Ltd filed Critical Immunotec Res Corp Ltd
Publication of MX9304925A publication Critical patent/MX9304925A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento de pacientes que tienen lesiones resultantes de células de cáncer y a una aplicación como una composición contra el cáncer, de un concentrado de proteína de suero no desnaturalizada.
MX9304925A 1992-08-13 1993-08-13 Composiciones terapeuticas contra el cancer para profilaxis o para el tratamiento de cancer. MX9304925A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92934792A 1992-08-13 1992-08-13

Publications (1)

Publication Number Publication Date
MX9304925A true MX9304925A (es) 1994-08-31

Family

ID=25457715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304925A MX9304925A (es) 1992-08-13 1993-08-13 Composiciones terapeuticas contra el cancer para profilaxis o para el tratamiento de cancer.

Country Status (15)

Country Link
EP (1) EP0655925B1 (es)
JP (2) JP4115515B2 (es)
KR (1) KR100297610B1 (es)
CN (1) CN1088095A (es)
AT (1) ATE265217T1 (es)
AU (1) AU687356B2 (es)
CA (1) CA2142277C (es)
CZ (1) CZ295849B6 (es)
DE (1) DE69333497T2 (es)
IL (1) IL106576A (es)
MX (1) MX9304925A (es)
NZ (1) NZ254704A (es)
TW (1) TW380051B (es)
WO (1) WO1994004168A1 (es)
ZA (1) ZA935918B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
TWI438675B (zh) 2010-04-30 2014-05-21 Ibm 提供情境感知援助說明之方法、裝置及電腦程式產品
CN102232556A (zh) * 2010-04-30 2011-11-09 李德远 一种抗偏二甲肼的食品添加剂
BR112014013565A2 (pt) * 2011-12-07 2019-09-24 Arla Foods Amba variante da opn para uso no tratamento ou prevenção de câncer envolvendo pelo menos um tumor canceroso, método de tratamento ou prevenção do câncer, composição farmacêutica e suplemento nutricional
DE102014001037A1 (de) * 2014-01-25 2015-07-30 Gea Tds Gmbh Verfahren und Vorrichtung zur Reduzierung des Wachstums thermophiler Keime in Magermilch
CN104146269B (zh) * 2014-07-28 2015-08-19 苏喜生 一种用于抗偏二甲肼的应激食品添加剂及其制备方法
CN105831769A (zh) * 2015-02-04 2016-08-10 张亚武 一种细胞内/细胞间对癌症抑制之食物
WO2018057514A1 (en) 2016-09-23 2018-03-29 Immunotec Inc. Compositions for restoring gene expression in neuropsychiatric or neurodegenerative disorders
CA2970699A1 (en) 2017-06-14 2018-12-14 Elizabeth E. Ignowski Compositions for increasing resilience to traumatic brain injury
WO2019027974A1 (en) 2017-07-31 2019-02-07 Immunotec Inc. COMPOSITIONS AND METHODS FOR TREATING AUTISM SPECTRUM DISORDER

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3628010A1 (de) * 1986-08-19 1988-02-25 Astra Chem Gmbh Arzneimittel fuer die verwendung bei der behandlung von hypertonie
DE3870247D1 (de) * 1988-12-21 1992-05-21 Siemens Ag Schienenfahrzeug.
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement
JPH03216156A (ja) * 1990-01-22 1991-09-24 Gustavo Bounous 生物学的に活性なホエータンパク質組成物、その製法および組成物の使用法

Also Published As

Publication number Publication date
JP4115515B2 (ja) 2008-07-09
NZ254704A (en) 1997-08-22
IL106576A0 (en) 1993-12-08
CA2142277A1 (en) 1994-03-03
KR950702837A (ko) 1995-08-23
CN1088095A (zh) 1994-06-22
DE69333497D1 (de) 2004-06-03
KR100297610B1 (ko) 2001-10-24
TW380051B (en) 2000-01-21
WO1994004168A1 (en) 1994-03-03
IL106576A (en) 2000-08-13
AU4693793A (en) 1994-03-15
ZA935918B (en) 1994-03-09
EP0655925A1 (en) 1995-06-07
DE69333497T2 (de) 2005-01-13
CA2142277C (en) 2000-01-18
JPH08500108A (ja) 1996-01-09
EP0655925B1 (en) 2004-04-28
CZ28395A3 (en) 1995-10-18
JP2008115194A (ja) 2008-05-22
CZ295849B6 (cs) 2005-11-16
AU687356B2 (en) 1998-02-26
ATE265217T1 (de) 2004-05-15

Similar Documents

Publication Publication Date Title
AU4835693A (en) Pharmaceutical composition comprising phosphatase or a derivative thereof
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
ATE247666T1 (de) Wasserlöslische prodrugs von 2,6- diisopropylphenol-analoga
CY1112927T1 (el) Αντισωματα κατα της ανθρωπινης il-12
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
NZ314839A (en) 1,25-Dihydroxy-16,23Z-diene-20-epi-16-ene-cholecalciferol (Vitamin D3) analogues
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
MX9304925A (es) Composiciones terapeuticas contra el cancer para profilaxis o para el tratamiento de cancer.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE69637178D1 (de) N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
EP0347899A3 (en) Pharmaceutical compositions on egg shell basis and their preparation and use
EP0699444A3 (en) Composition for the treatment of intestinal wounds or ulcers containing proteins, carbohydrates and fat
AU5691796A (en) Terpenoidic derivatives useful as antitumor agents
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ZA966953B (en) Pharmaceutical composition.
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
DK1001756T3 (da) Synergistisk virkende sammensætninger til selektkiv bekæmpelse af tumorvæv
PT1007085E (pt) Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
KR0177821B1 (en) Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans
MX9700929A (es) Metodos y composiciones utiles en la profilaxis y terapia de condiciones relacionadas a la endotoxina.

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration